让你更懂肿瘤治疗 放疗说 2023-09-19 06:03 发表于北京。参考文献:1. Jung HK， Tae CH， Lee HA， et al. Treatment pattern and overall survival in esophageal cancer during a 13-year period: A nationwide cohort study of 6， 354 Korean patients2. Liu Y， Bao Y， Yang X， et al. Efficacy and safety of neoadjuvant immunotherapy combined with chemoradiotherapy or chemotherapy in esophageal cancer: A systematic review and meta-analysis3. Park S， Sun JM， Choi YL， et al. Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled， randomized， double-blind， phase Ⅱ study4. Zhang W， Yan C， Zhang T， et al. Addition of camrelizumab to docetaxel， cisplatin， and radiation therapy in patients with locally advanced esophageal squamous cell carcinoma: a phase 1b study5. Zhu Y， Wen J， Li Q， et al. Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma : a single-arm， phase 2 trial6. Wang X， Li B. Two-stage phase Ⅱ study of envafolimab combined with endostar and concurrent chemoradiotherapy in treatment of unresectable locally advanced esophageal squamous cell carcinoma: preliminary results of stage 17. Wu X， Li Y， Zhang K， et al. Immunotherapy with or without radiotherapy for metastatic or recurrent esophageal squamous cell carcinoma: A real-world study8. Zhao W， Ke S， Cai X， et al. Radiotherapy plus camrelizumab and irinotecan for oligometastatic esophageal squamous cell carcinoma patients after first-line immunotherapy plus chemotherapy failure: An open-label， single-arm， phase Ⅱ trial。
70岁的李林（化名）吃饭的时候总是“梗阻”，到医院检查被确诊为局部晚期食管癌，已经丧失手术机会。以往像他这类食管癌的治疗方法只有放化疗，三年生存率不到40%。李林选择加入一项临床研究，尝试免疫治疗联合放化疗来治疗食管癌。
南方医科大学南方医院称，2016年，湖北天门的黄先生到该院放疗科就诊，病因为：左侧肾癌在行肾癌切除术后，肿瘤出现全身多发转移，其中转移至纵隔的肿大淋巴结压迫食管导致吞咽困难。通过“立体定向放疗+免疫”疗法及多次随访复查，黄先生的肿瘤全部消失，如今七年过去，未见肿瘤复发。
